Abbott Diagnostics Exhibits POC Diagnostics Solutions at AACC
|
By LabMedica International staff writers Posted on 05 Aug 2019 |

Image: The ID NOW isothermal system for the qualitative detection of infectious diseases (Photo courtesy of Abbott Diagnostics).
Abbott Diagnostics (Lake Bluff, IL, USA) exhibited its range of rapid Point-of-Care (POC) diagnostics solutions at the 71st AACC Annual Scientific Meeting & Clinical Lab Expo held in Anaheim, California, USA. The annual event held by the American Association for Clinical Chemistry (AACC) showcased the cutting-edge science and technology shaping the future of laboratory medicine.
At AACC 2019, Abbott exhibited ID NOW, a rapid, instrument-based, isothermal system for the qualitative detection of infectious diseases. The ID NOW isothermal nucleic acid amplification technology provides molecular results in just minutes, allowing users to make effective clinical decisions sooner. ID NOW is significantly faster than other molecular methods and more accurate than conventional rapid tests and can have a positive impact in any healthcare setting.
Abbott also showcased its Afinion 2 Analyzer, a compact, rapid, multi-assay analyzer that provides valuable near patient testing at the POC. Designed to enable simple and fast on-the-spot testing, regardless of the sample type, the Afinion System makes it fast and easy to test quantitative determinations of HbA1c, Lipid Panel, ACR, and CRP. By delivering accurate results during patient consultation, it eliminates the need to send patients to the lab or spend time tracking down their results for improved patient management.
Abbott also demonstrated its RALS POC Data management system, which provides immediate and remote access to patient and quality control results from the POCT devices being used. Unlike data management solutions that use a device-specific data manager between the device and their system, the RALS System can manage all devices, all patient results, all operators, all consumables and all reports —from a single-system solution.
At AACC 2019, Abbott exhibited ID NOW, a rapid, instrument-based, isothermal system for the qualitative detection of infectious diseases. The ID NOW isothermal nucleic acid amplification technology provides molecular results in just minutes, allowing users to make effective clinical decisions sooner. ID NOW is significantly faster than other molecular methods and more accurate than conventional rapid tests and can have a positive impact in any healthcare setting.
Abbott also showcased its Afinion 2 Analyzer, a compact, rapid, multi-assay analyzer that provides valuable near patient testing at the POC. Designed to enable simple and fast on-the-spot testing, regardless of the sample type, the Afinion System makes it fast and easy to test quantitative determinations of HbA1c, Lipid Panel, ACR, and CRP. By delivering accurate results during patient consultation, it eliminates the need to send patients to the lab or spend time tracking down their results for improved patient management.
Abbott also demonstrated its RALS POC Data management system, which provides immediate and remote access to patient and quality control results from the POCT devices being used. Unlike data management solutions that use a device-specific data manager between the device and their system, the RALS System can manage all devices, all patient results, all operators, all consumables and all reports —from a single-system solution.
Latest AACC 2019 News
- Instrumentation Laboratory Presents New IVD Testing System
- Quidel Welcomes Newest Member of Triage Family
- ERBA Mannheim Unveils Next-Generation Automation
- Roche Demonstrates How Health Networks Are Driving Change in Labs and Beyond
- BioMérieux Spotlights Diagnostic Solutions in Use of Antibiotics
- Thermo Shows New Clinical Innovations
- Randox Launches New Innovations
- Streck Introduces Three New Antibiotic Resistance Detection Kits
- EKF Diagnostics Highlights Assay for Diabetes Patient Monitoring
- Sysmex America Exhibits New Products, Automation and Quality Solutions
- BBI Solutions Showcases Mobile Solutions Capabilities at AACC 2019
- MedTest Dx Releases New Product Line for Drugs of Abuse Testing
- Mesa Biotech Launches Molecular Test System at AACC 2019
- Ortho Clinical Diagnostics Highlights Groundbreaking Lab Technology
- Beckman Coulter Demonstrates Latest Innovations in Lab Medicine
- Orion Diagnostica Showcases Range of Products in Anaheim
Channels
Clinical Chemistry
view channel
Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care
Timely evaluation of cognitive symptoms in primary care is often limited by restricted access to specialized diagnostics and invasive confirmatory procedures. Clinicians need accessible tools to determine... Read more
Existing Hospital Analyzers Can Identify Fake Liquid Medical Products
Counterfeit and substandard medicines remain a serious global health threat, with World Health Organization estimates suggesting that 10.5% of medicines in low- and middle-income countries are either fake... Read moreMolecular Diagnostics
view channel
New Genome Sequencing Technique Measures Epstein-Barr Virus in Blood
The Epstein–Barr virus (EBV) infects up to 95% of adults worldwide and remains in the body for life. While usually kept under control, the virus is linked to cancers such as Hodgkin’s lymphoma and autoimmune... Read more
Blood Test Boosts Early Detection of Brain Cancer
Brain and central nervous system (CNS) tumors are often diagnosed at an advanced stage, when treatment options are limited, and survival rates remain low. Around 300,000 new cases are diagnosed each year... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Three-Test Panel Launched for Detection of Liver Fluke Infections
Parasitic liver fluke infections remain endemic in parts of Asia, where transmission commonly occurs through consumption of raw freshwater fish or aquatic plants. Chronic infection is a well-established... Read more
Rapid Test Promises Faster Answers for Drug-Resistant Infections
Drug-resistant pathogens continue to pose a growing threat in healthcare facilities, where delayed detection can impede outbreak control and increase mortality. Candida auris is notoriously difficult to... Read more
CRISPR-Based Technology Neutralizes Antibiotic-Resistant Bacteria
Antibiotic resistance has accelerated into a global health crisis, with projections estimating more than 10 million deaths per year by 2050 as drug-resistant “superbugs” continue to spread.... Read more
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read morePathology
view channel
Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more
New AI-Driven Platform Standardizes Tuberculosis Smear Microscopy Workflow
Sputum smear microscopy remains central to tuberculosis treatment monitoring and follow-up, particularly in high‑burden settings where serial testing is routine. Yet consistent, repeatable bacillary assessment... Read more
AI Tool Uses Blood Biomarkers to Predict Transplant Complications Before Symptoms Appear
Stem cell and bone marrow transplants can be lifesaving, but serious complications may arise months after patients leave the hospital. One of the most dangerous is chronic graft-versus-host disease, in... Read moreTechnology
view channel
Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
More than 7 million Americans live with Alzheimer’s disease, and related health and long-term care costs are projected to reach nearly USD 400 billion in 2025. The disease has no cure, and symptoms often... Read more
AI-Powered Biomarker Predicts Liver Cancer Risk
Liver cancer, or hepatocellular carcinoma, causes more than 800,000 deaths worldwide each year and often goes undetected until late stages. Even after treatment, recurrence rates reach 70% to 80%, contributing... Read more
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreIndustry
view channel
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more








